United Therapeutics (UTHR) Total Current Liabilities (2009 - 2026)

United Therapeutics has disclosed Total Current Liabilities across 18 years of filings, most recently posting $599.1 million for Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $599.1 million, down 16.96% year-over-year; the trailing twelve-month figure through Mar 2026 was $599.1 million (down 16.96% YoY), and the FY2025 annual result was $560.6 million, down 24.05% from the prior year.
• Total Current Liabilities came in at $599.1 million for Q1 2026 at United Therapeutics, up from $560.6 million in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $873.4 million in Q3 2024 to a low of $292.6 million in Q1 2022.
• The 5-year median for Total Current Liabilities is $560.6 million (2025), against an average of $575.6 million.
• Across the five-year window, Total Current Liabilities soared 165.13% in 2024 and plunged 37.45% in 2025, its largest moves.
• United Therapeutics' Total Current Liabilities stood at $343.2 million in 2022, then soared by 134.38% to $804.4 million in 2023, then fell by 8.24% to $738.1 million in 2024, then slipped by 24.05% to $560.6 million in 2025, then advanced by 6.87% to $599.1 million in 2026.
• The last three Total Current Liabilities figures came in at $599.1 million (Q1 2026), $560.6 million (Q4 2025), and $546.3 million (Q3 2025), per Business Quant data.